182 related articles for article (PubMed ID: 32762992)
1. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments.
Coquerelle S; Darlington M; Michel M; Durand M; Borget I; Baffert S; Marino P; Perrier L; Durand-Zaleski I;
Value Health; 2020 Jul; 23(7):898-906. PubMed ID: 32762992
[TBL] [Abstract][Full Text] [Related]
2. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
5. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract][Full Text] [Related]
6. Routine application of next-generation sequencing testing in uro-oncology-Are we ready for the next step of personalised medicine?
Rodler S; Jung A; Greif PA; Rühlmann K; Apfelbeck M; Tamalunas A; Kretschmer A; Schulz GB; Szabados B; Stief C; Heinemann V; Westphalen CB; Casuscelli J
Eur J Cancer; 2021 Mar; 146():1-10. PubMed ID: 33535139
[TBL] [Abstract][Full Text] [Related]
7. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
[TBL] [Abstract][Full Text] [Related]
8. Mutation Profiling of Clinically Advanced Cancers Using Next-Generation Sequencing for Targeted Therapy: A Lifespan Experience.
Friedman K; Resnick MB; Safran H
R I Med J (2013); 2015 Oct; 98(10):16-20. PubMed ID: 26422540
[TBL] [Abstract][Full Text] [Related]
9. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
10. High-throughput detection of clinically targetable alterations using next-generation sequencing.
Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Sabari JK; Offin M; Stephens D; Ni A; Lee A; Pavlakis N; Clarke S; Diakos CI; Datta S; Tandon N; Martinez A; Myers ML; Makhnin A; Leger Y; Yu HA; Paik PK; Chaft JE; Kris MG; Jeon JO; Borsu LA; Ladanyi M; Arcila ME; Hernandez J; Henderson S; Shaffer T; Garg K; DiPasquo D; Raymond CK; Lim LP; Li M; Hellmann MD; Drilon A; Riely GJ; Rusch VW; Jones DR; Rimner A; Rudin CM; Isbell JM; Li BT
J Natl Cancer Inst; 2019 Jun; 111(6):575-583. PubMed ID: 30496436
[TBL] [Abstract][Full Text] [Related]
12. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
[TBL] [Abstract][Full Text] [Related]
13. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
Johnson DB; Dahlman KH; Knol J; Gilbert J; Puzanov I; Means-Powell J; Balko JM; Lovly CM; Murphy BA; Goff LW; Abramson VG; Crispens MA; Mayer IA; Berlin JD; Horn L; Keedy VL; Reddy NM; Arteaga CL; Sosman JA; Pao W
Oncologist; 2014 Jun; 19(6):616-22. PubMed ID: 24797823
[TBL] [Abstract][Full Text] [Related]
14. Clinical application of amplicon-based next-generation sequencing in cancer.
Chang F; Li MM
Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
[TBL] [Abstract][Full Text] [Related]
15. [THE IMPACT OF MOLECULAR PROFILING USING NEXT-GENERATION SEQUENCING IN ADVANCED LUNG CANCER].
Belilovski Rozenblum A; Ilouze M; Dudnik E; Soussan-Gutman L; Dvir A; Peled N
Harefuah; 2017 Nov; 156(11):686-691. PubMed ID: 29198084
[TBL] [Abstract][Full Text] [Related]
16. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.
Dagogo-Jack I; Robinson H; Mino-Kenudson M; Farago AF; Kamesan V; Iafrate AJ; Shaw AT; Lennerz JK
J Thorac Oncol; 2019 May; 14(5):835-843. PubMed ID: 30660796
[TBL] [Abstract][Full Text] [Related]
17. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
Barlesi F; Mazieres J; Merlio JP; Debieuvre D; Mosser J; Lena H; Ouafik L; Besse B; Rouquette I; Westeel V; Escande F; Monnet I; Lemoine A; Veillon R; Blons H; Audigier-Valette C; Bringuier PP; Lamy R; Beau-Faller M; Pujol JL; Sabourin JC; Penault-Llorca F; Denis MG; Lantuejoul S; Morin F; Tran Q; Missy P; Langlais A; Milleron B; Cadranel J; Soria JC; Zalcman G;
Lancet; 2016 Apr; 387(10026):1415-1426. PubMed ID: 26777916
[TBL] [Abstract][Full Text] [Related]
18. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group.
Loong HH; Shimizu T; Prawira A; Tan AC; Tran B; Day D; Tan DSP; Ting FIL; Chiu JW; Hui M; Wilson MK; Prasongsook N; Koyama T; Reungwetwattana T; Tan TJ; Heong V; Voon PJ; Park S; Tan IB; Chan SL; Tan DSW
ESMO Open; 2023 Aug; 8(4):101586. PubMed ID: 37356359
[TBL] [Abstract][Full Text] [Related]
20. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Li W; Qiu T; Guo L; Ying J; Zhou A
Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]